AbbVie Inc (ABBV)vsAlumis Inc (ALMS)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
ALMS
Alumis Inc
$19.06
-6.52%
HEALTHCARE · Cap: $2.55B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 747567% more annual revenue ($62.82B vs $8.40M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ALMS
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for ALMS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
0.0% margin — thin
ROE of -41.9% — below average capital efficiency
Revenue declined 90.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : ALMS
The strongest argument for ALMS centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : ALMS
The primary concerns for ALMS are EPS Growth, Profit Margin, Return on Equity.
Key Dynamics to Monitor
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 24/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Alumis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alumis Inc. (ALMS) stands at the forefront of the aluminum industry, specializing in the development and commercialization of high-performance aluminum products tailored for essential sectors, including automotive, aerospace, and construction. Through its proprietary technologies and a steadfast commitment to sustainable manufacturing, Alumis not only advances material science but also emphasizes environmental responsibility. The company's robust focus on research and development positions it to effectively seize emerging market opportunities, with a diverse product portfolio designed to meet evolving client needs. With a dedication to operational excellence and sustainable practices, Alumis is strategically poised for long-term growth and value creation for its stakeholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?